What is the CanAssist Breast test?

CanAssist Breast is a prognostic test that helps predict the risk of breast cancer recurrence and supports oncologists in personalizing treatment plans.

Who can benefit from the CanAssist Breast test?

It is suitable for patients diagnosed with early-stage, hormone receptor-positive breast cancer to determine their recurrence risk.

How accurate is the CanAssist Breast test?

CanAssist Breast has been validated on South Asian and Caucasian populations, demonstrating high accuracy in predicting recurrence risk.

Clinical Research Validating Breast Cancer Recurrence Risk Tests

Advisory Meeting, Kolkata

Events and Conferences

December, 2022

CanAssist Breast Advisory Meeting, Kolkata

View

Advisory Meeting, Delhi

Events and Conferences

December, 2022

CanAssist Breast Advisory Meeting, Delhi

View

Breast Cancer Research & Treatment

Scientific Publication by OncoStem

September, 2022

A comparative analysis of recurrence risk predictions in ER+/HER2−early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast

View

South Asian Journal of Cancer

Scientific Publication by Renowned Oncologists Worldwide

August, 2022

Ashok Vaid et al: Robust Guidelines for the Management of HR+/HER2 EBC: Crucial Value of CanAssist Breast

View

Annals of Oncology - Abstract Book of ESMO Breast Cancer 2022

Scientific Publication by OncoStem

April, 2022

9P-Long term recurrence risk predictions by CanAssist Breast in a sub-cohort of TEAM

View

The Breast

Scientific Publication by OncoStem

February, 2022

A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort

View

International Journal of Clinical & Experimental Pathology

Scientific Publication by OncoStem

October, 2021

Validation of CanAssist Breast immunohistochemistry biomarkers on an automated platform and its applicability in tissue microarrayn

View

Scientific Publications